BACKGROUND: Long-term oral corticosteroids have been a mainstay of maintenance immunosuppression in pediatric heart transplantation. In this study, we report early clinical outcomes in a cohort of pediatric heart transplant recipients managed using a steroid-avoidance protocol. METHODS: Of the 70 patients who underwent heart transplantation during the study period, 55 eligible recipients, including 49 non-sensitized and 6 sensitized (all 55 with negative crossmatch) patients, entered a steroid-avoidance immunosuppression protocol consisting of thymoglobin induction followed by a 2-drug, tacrolimus-based, corticosteroid-free regimen. The primary outcome variable was freedom from moderate rejection (International Society for Heart and Lung Transplantation [ISHLT] Grade 2R/3A or antibody-mediated rejection). RESULTS: The median age at transplant was 7.1 years (range 2 weeks to 22 years) and median follow-up was 19 months (range 2 to 46 months). Fifty patients survived to discharge after transplantation. Of these patients, 2 (4%) were discharged on steroids and 8 (16%) started on maintenance steroids at follow-up. Rejection was diagnosed in 8 patients (Grade 2R cellular rejection in 3 and antibody-mediated rejection in 5). Freedom from rejection was 92% at 6 months (95% confidence interval [CI] 80% to 97%) and 87% at 1 year (CI 73% to 94%). Post-transplant survival was 91% at 6 months (CI 79% to 96%) and 88% at 12 and 24 months (CI 75% to 95%). There was 1 death due to rejection (antibody-mediated) 8 months after transplantation. CONCLUSIONS: An immunosuppression protocol consisting of induction followed by corticosteroid avoidance appears to achieve acceptable rejection rates during the first year post-transplant in pediatric heart transplant recipients. Copyright (c) 2010 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.
BACKGROUND: Long-term oral corticosteroids have been a mainstay of maintenance immunosuppression in pediatric heart transplantation. In this study, we report early clinical outcomes in a cohort of pediatric heart transplant recipients managed using a steroid-avoidance protocol. METHODS: Of the 70 patients who underwent heart transplantation during the study period, 55 eligible recipients, including 49 non-sensitized and 6 sensitized (all 55 with negative crossmatch) patients, entered a steroid-avoidance immunosuppression protocol consisting of thymoglobin induction followed by a 2-drug, tacrolimus-based, corticosteroid-free regimen. The primary outcome variable was freedom from moderate rejection (International Society for Heart and Lung Transplantation [ISHLT] Grade 2R/3A or antibody-mediated rejection). RESULTS: The median age at transplant was 7.1 years (range 2 weeks to 22 years) and median follow-up was 19 months (range 2 to 46 months). Fifty patients survived to discharge after transplantation. Of these patients, 2 (4%) were discharged on steroids and 8 (16%) started on maintenance steroids at follow-up. Rejection was diagnosed in 8 patients (Grade 2R cellular rejection in 3 and antibody-mediated rejection in 5). Freedom from rejection was 92% at 6 months (95% confidence interval [CI] 80% to 97%) and 87% at 1 year (CI 73% to 94%). Post-transplant survival was 91% at 6 months (CI 79% to 96%) and 88% at 12 and 24 months (CI 75% to 95%). There was 1 death due to rejection (antibody-mediated) 8 months after transplantation. CONCLUSIONS: An immunosuppression protocol consisting of induction followed by corticosteroid avoidance appears to achieve acceptable rejection rates during the first year post-transplant in pediatric heart transplant recipients. Copyright (c) 2010 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.
Authors: Mysore S Anil Kumar; Michael Heifets; Michael J Moritz; Muhammad I Saeed; Shahid M Khan; Billie Fyfe; Nedjema Sustento-Riodeca; Joshua N Daniel; Aparna Kumar Journal: Transplantation Date: 2006-03-27 Impact factor: 4.939
Authors: Mohamad H Yamani; David O Taylor; Jennifer Czerr; Christinna Haire; Richard Kring; Lingmei Zhou; Robert Hobbs; Nicholas Smedira; Randall C Starling Journal: Clin Transplant Date: 2008 Jan-Feb Impact factor: 2.863
Authors: Mark M Boucek; Paul Aurora; Leah B Edwards; David O Taylor; Elbert P Trulock; Jason Christie; Fabienne Dobbels; Axel O Rahmel; Berkeley M Keck; Marshall I Hertz Journal: J Heart Lung Transplant Date: 2007-08 Impact factor: 10.247
Authors: D A Fullerton; D N Campbell; S D Jones; J Jaggers; J M Brown; M M Wollmering; F L Grover; C Mashburn; M Luna; H M Sondheimer Journal: Ann Thorac Surg Date: 1995-04 Impact factor: 4.330
Authors: David N Rosenthal; Clifford Chin; Kyra Nishimura; Stanton B Perry; Robert C Robbins; Bruce Reitz; Daniel Bernstein; Jeffrey A Feinstein Journal: J Heart Lung Transplant Date: 2004-03 Impact factor: 10.247
Authors: Scott R Auerbach; Jane Gralla; David N Campbell; Shelley D Miyamoto; Biagio A Pietra Journal: Transplantation Date: 2014-02-27 Impact factor: 4.939
Authors: Ryan Butts; Melanie Davis; Andrew Savage; Ali Burnette; Minoo Kavarana; Scott Bradley; Andrew Atz; Paul J Nietert Journal: Transplantation Date: 2017-06 Impact factor: 4.939
Authors: Andreas Zuckermann; Uwe Schulz; Tobias Deuse; Arjang Ruhpawar; Jan D Schmitto; Andres Beiras-Fernandez; Stephan Hirt; Martin Schweiger; Laurenz Kopp-Fernandes; Markus J Barten Journal: Transpl Int Date: 2014-11-11 Impact factor: 3.782